Table 4.
Dose reductions and discontinuations
| Characteristic | PTCL (N = 131) | CTCL (N = 102) |
|---|---|---|
| Dose reduction due to adverse events, n (%) |
14 (11) |
14 (14) |
| Dose interruptions due to adverse events, n (%) |
61 (47) |
35 (34) |
| Discontinuation, n (%) |
|
|
| Progressive disease |
78 (60) |
22 (22) |
| Adverse event |
22 (17) |
24 (24) |
| Adverse event related to romidepsin treatment |
11 (8) |
17 (17) |
| Othera | 7 (5) | 26 (26) |
CTCL, cutaneous T-cell lymphoma; PTCL, peripheral T-cell lymphoma.
aMost often refers to withdrawal of consent.